{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:20:51Z","timestamp":1790194851743,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000038","name":"United States Food and Drug Administration","doi-asserted-by":"crossref","award":["Contract No. 75F40119C10150"],"award-info":[{"award-number":["Contract No. 75F40119C10150"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000038","name":"United States Food and Drug Administration","doi-asserted-by":"crossref","award":["Contract No. 75F40119C10150"],"award-info":[{"award-number":["Contract No. 75F40119C10150"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000038","name":"United States Food and Drug Administration","doi-asserted-by":"crossref","award":["Contract No. 75F40119C10150"],"award-info":[{"award-number":["Contract No. 75F40119C10150"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000038","name":"United States Food and Drug Administration","doi-asserted-by":"crossref","award":["Contract No. 75F40119C10150"],"award-info":[{"award-number":["Contract No. 75F40119C10150"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000038","name":"United States Food and Drug Administration","doi-asserted-by":"crossref","award":["Contract No. 75F40119C10150"],"award-info":[{"award-number":["Contract No. 75F40119C10150"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000038","name":"United States Food and Drug Administration","doi-asserted-by":"crossref","award":["Contract No. 75F40119C10150"],"award-info":[{"award-number":["Contract No. 75F40119C10150"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000038","name":"United States Food and Drug Administration","doi-asserted-by":"crossref","award":["Contract No. 75F40119C10150"],"award-info":[{"award-number":["Contract No. 75F40119C10150"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Acute block of hERG channels is the most common mechanism underlying drug-induced QT\n                    <jats:sub>C<\/jats:sub>\n                    prolongation and potentially fatal\n                    <jats:italic>Torsade de Pointes<\/jats:italic>\n                    arrhythmia. Updates to ICH E14 Q&amp;As now allow for using negative nonclinical data, including hERG, to support QT\n                    <jats:sub>C<\/jats:sub>\n                    risk assessment in late-stage clinical development. To interpret the hERG results, understanding hERG assay reproducibility or hERG data variability is pivotal. Protocol and best practice recommendations have been provided with the goal of minimizing lab-to-lab data differences, but the impact remains unclear. To fill this knowledge gap, hERG data from a HESI-coordinated multi-laboratory study were leveraged. Using standardized protocol and following best practices for patch clamp studies, five laboratories tested 28 drugs using the manual patch clamp technique. Systematic differences in block potencies were observed for data generated by one laboratory for the first 21 drugs, and these differences disappeared for the last seven drugs. Exposure, pharmacological sensitivity of the cell lines, and cell\/data qualities were ruled out as the factors underlying systematic differences. All laboratories retested two drugs and obtained results within 1.6X of the initial testings, except for another laboratory that obtained data for one drug that differed from its initial testing by 7.6X. Descriptive statistics and meta-analysis were applied to the dataset to estimate what the distribution in hERG block potencies would be if a laboratory were to test the same drug repeatedly. This measure, or hERG data variability, was ~\u20095X. Based on these results, hERG block potency values within 5X of each other should not be considered different, since these values are within the natural data distribution of the hERG assay; laboratory-specific safety margin threshold may be required to account for systematic data differences.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-15761-8","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T08:44:45Z","timestamp":1755333885000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Multi-laboratory comparisons of manual patch clamp hERG data generated using standardized protocols and following ICH S7B Q&amp;A 2.1 best practices"],"prefix":"10.1038","volume":"15","author":[{"given":"Claudia","family":"Alvarez Baron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Thiebaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giri","family":"Vegesna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hui","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"DePalma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabyasachy","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isra","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Shadiqur Rashid","family":"Roni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omnia A.","family":"Ismaiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali K.","family":"Matta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manni","family":"Mashaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Johannesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiansong","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Hebeisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bruening-Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Beck","family":"Pierson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy W.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"key":"15761_CR1","unstructured":"Anonymous ICH S7B: the non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. The international Council for harmonisation of technical requirements for pharmaceuticals for human use (ICH). (2005). https:\/\/database.ich.org\/sites\/default\/files\/S7B_Guideline.pdf."},{"key":"15761_CR2","unstructured":"Anonymous & ICH E14. : The clinical evaluation of qt\/qtc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs. The international Council for harmonisation of technical requirements for pharmaceuticals for human use (ICH). (2005). https:\/\/database.ich.org\/sites\/default\/files\/E14_Guideline.pdf."},{"key":"15761_CR3","unstructured":"Anonymous & ICH E14\/S7B IWG. : Questions and answers: clinical and nonclinical evaluation of qt\/qtc interval prolongation and proarrhythmic potential.the international Council for harmonisation of technical requirements for pharmaceuticals for human use (ICH). (2022). https:\/\/database.ich.org\/sites\/default\/files\/ICH_E14-S7B_QAs_Step2_2020_0827_0.pdf."},{"key":"15761_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.vascn.2004.06.003","volume":"50","author":"GE Kirsch","year":"2004","unstructured":"Kirsch, G. E. et al. Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J. Pharmacol. Toxicol. Methods. 50, 93\u2013101. https:\/\/doi.org\/10.1016\/j.vascn.2004.06.003 (2004).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"15761_CR5","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.hrthm.2005.04.029","volume":"2","author":"J Guo","year":"2005","unstructured":"Guo, J., Zhan, S., Lees-Miller, J. P., Teng, G. & Duff, H. J. Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37 degrees C and 42 degrees C. Heart Rhythm. 2, 860\u2013866. https:\/\/doi.org\/10.1016\/j.hrthm.2005.04.029 (2005).","journal-title":"Heart Rhythm"},{"key":"15761_CR6","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1124\/mol.117.111534","volume":"94","author":"MJ Windley","year":"2018","unstructured":"Windley, M. J., Lee, W., Vandenberg, J. I. & Hill, A. P. The temperature dependence of kinetics associated with drug block of hERG channels is Compound-Specific and an important factor for proarrhythmic risk prediction. Mol. Pharmacol. 94, 760\u2013769. https:\/\/doi.org\/10.1124\/mol.117.111534 (2018).","journal-title":"Mol. Pharmacol."},{"key":"15761_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.vascn.2005.04.008","volume":"52","author":"JA Yao","year":"2005","unstructured":"Yao, J. A. et al. Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature. J. Pharmacol. Toxicol. Methods. 52, 146\u2013153. https:\/\/doi.org\/10.1016\/j.vascn.2005.04.008 (2005).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"15761_CR8","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1038\/sj.bjp.0707356","volume":"151","author":"D Stork","year":"2007","unstructured":"Stork, D. et al. State dependent dissociation of HERG channel inhibitors. Br. J. Pharmacol. 151, 1368\u20131376. https:\/\/doi.org\/10.1038\/sj.bjp.0707356 (2007).","journal-title":"Br. J. Pharmacol."},{"key":"15761_CR9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.vascn.2010.02.007","volume":"61","author":"JT Milnes","year":"2010","unstructured":"Milnes, J. T., Witchel, H. J., Leaney, J. L., Leishman, D. J. & Hancox, J. C. Investigating dynamic protocol-dependence of hERG potassium channel Inhibition at 37 degrees C: Cisapride versus dofetilide. J. Pharmacol. Toxicol. Methods. 61, 178\u2013191. https:\/\/doi.org\/10.1016\/j.vascn.2010.02.007 (2010).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"15761_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2017.08.006","author":"J Sheng","year":"2017","unstructured":"Sheng, J. et al. Characterization of loperamide-mediated block of hERG channels at physiological temperature and its proarrhythmia propensity. J. Pharmacol. Toxicol. Methods. https:\/\/doi.org\/10.1016\/j.vascn.2017.08.006 (2017).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"15761_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.vascn.2008.10.004","volume":"59","author":"JC Brimecombe","year":"2009","unstructured":"Brimecombe, J. C., Kirsch, G. E. & Brown, A. M. Test Article concentrations in the hERG assay: losses through the perfusion, solubility and stability. J. Pharmacol. Toxicol. Methods. 59, 29\u201334. https:\/\/doi.org\/10.1016\/j.vascn.2008.10.004 (2009).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"15761_CR12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.yrtph.2013.10.001","volume":"67","author":"S Goineau","year":"2013","unstructured":"Goineau, S., Lacaud, J. L., Legrand, C., Eveilleaux, E. & Castagne, V. In vitro safety cardiovascular Pharmacology studies: impact of formulation Preparation and analysis. Regul. Toxicol. Pharmacol. 67, 499\u2013505. https:\/\/doi.org\/10.1016\/j.yrtph.2013.10.001 (2013).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"15761_CR13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.vascn.2011.08.004","volume":"64","author":"Y Qu","year":"2011","unstructured":"Qu, Y., Schnier, P., Zanon, R. & Vargas, H. M. hERG potency estimates based upon dose solution analysis: what have we learned? J. Pharmacol. Toxicol. Methods. 64, 251\u2013257. https:\/\/doi.org\/10.1016\/j.vascn.2011.08.004 (2011).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"15761_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.vascn.2006.05.001","volume":"54","author":"LA Hanson","year":"2006","unstructured":"Hanson, L. A. et al. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J. Pharmacol. Toxicol. Methods. 54, 116\u2013129. https:\/\/doi.org\/10.1016\/j.vascn.2006.05.001 (2006).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"15761_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.vascn.2016.06.002","volume":"81","author":"T Colatsky","year":"2016","unstructured":"Colatsky, T. et al. The comprehensive in vitro proarrhythmia assay (CiPA) initiative - Update on progress. J. Pharmacol. Toxicol. Methods. 81, 15\u201320. https:\/\/doi.org\/10.1016\/j.vascn.2016.06.002 (2016).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"15761_CR16","doi-asserted-by":"publisher","first-page":"107193","DOI":"10.1016\/j.vascn.2022.107193","volume":"117","author":"C Alvarez Baron","year":"2022","unstructured":"Alvarez Baron, C. et al. hERG block potencies for 5 positive control drugs obtained per ICH E14\/S7B q&as best practices: impact of recording temperature and drug loss. J. Pharmacol. Toxicol. Methods. 117, 107193. https:\/\/doi.org\/10.1016\/j.vascn.2022.107193 (2022).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"15761_CR17","unstructured":"Anonymous. Bioanalytical Method Validation - Guidance for Industry.U.S. Department of Health and Human Services - Food and Drug Administration. (2018). https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf."},{"key":"15761_CR18","doi-asserted-by":"publisher","first-page":"107229","DOI":"10.1016\/j.vascn.2022.107229","volume":"118","author":"TI King","year":"2022","unstructured":"King, T. I. et al. Determination of five positive control drugs in hERG external solution (buffer) by LC-MS\/MS to support in vitro hERG assay as recommended by ICH S7B. J. Pharmacol. Toxicol. Methods. 118, 107229. https:\/\/doi.org\/10.1016\/j.vascn.2022.107229 (2022).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"15761_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer, W. Conducting Meta-Analyses in R with the metafor package. J. Stat. Softw. 36, 1\u201348. https:\/\/doi.org\/10.18637\/jss.v036.i03 (2010).","journal-title":"J. Stat. Softw."},{"key":"15761_CR20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/jrsm.1562","volume":"13","author":"W Viechtbauer","year":"2022","unstructured":"Viechtbauer, W. & L\u00f3pez-L\u00f3pez, J. A. Location-scale models for meta-analysis. Res. Synth. Methods. 13, 697\u2013715. https:\/\/doi.org\/10.1002\/jrsm.1562 (2022).","journal-title":"Res. Synth. Methods"},{"key":"15761_CR21","first-page":"1","volume":"6","author":"AM Yahya","year":"1988","unstructured":"Yahya, A. M. & McElnay, J. C. D\u2019Arcy, P. F. Drug sorption to glass and plastics. Drug Metabol Drug Interact. 6, 1\u201345 (1988).","journal-title":"Drug Metabol Drug Interact."},{"key":"15761_CR22","doi-asserted-by":"publisher","first-page":"107524","DOI":"10.1016\/j.vascn.2024.107524","volume":"128","author":"DJ Leishman","year":"2024","unstructured":"Leishman, D. J. et al. Supporting an integrated QTc risk assessment using the hERG margin distributions for three positive control agents derived from multiple laboratories and on multiple occasions. J. Pharmacol. Toxicol. Methods. 128, 107524. https:\/\/doi.org\/10.1016\/j.vascn.2024.107524 (2024).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"15761_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.vascn.2013.04.007","volume":"68","author":"RC Elkins","year":"2013","unstructured":"Elkins, R. C. et al. Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment. J. Pharmacol. Toxicol. Methods. 68, 112\u2013122. https:\/\/doi.org\/10.1016\/j.vascn.2013.04.007 (2013).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"15761_CR24","doi-asserted-by":"publisher","first-page":"107213","DOI":"10.1016\/j.vascn.2022.107213","volume":"118","author":"ED Watt","year":"2022","unstructured":"Watt, E. D. et al. Use of high throughput ion channel profiling and statistical modeling to predict off-target arrhythmia risk - One pharma\u2019s experience and perspective. J. Pharmacol. Toxicol. Methods. 118, 107213. https:\/\/doi.org\/10.1016\/j.vascn.2022.107213 (2022).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"15761_CR25","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.1038\/s41598-020-62344-w","volume":"10","author":"J Kramer","year":"2020","unstructured":"Kramer, J. et al. Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in Recombinant cells. Sci. Rep. 10, 5627. https:\/\/doi.org\/10.1038\/s41598-020-62344-w (2020).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15761-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15761-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15761-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T21:03:25Z","timestamp":1755378205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15761-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15761"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-15761-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29995"}}